Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-77

Wrong again my friends

The value is in the developed drug and what it can be licensed for to big pharma

As indicated in webinar, this was the company Jackie was talking about at the AGM in November 2023, having scoured the earth looking for a solution to it's molecule using Starpharma's platform in ADC's

So in the 3-4 year development cycle getting it to POC and then on selling to big pharma we could be talking billions of dollars

22.5% of billions of dollars is a lot of monet

And as the CEO of Patalion mentioned, there could be inflection points along the way which might accelerate exit

All in all a very good announcement yesterday

I look forward to many more that will add value to Starpharma